Sibrotuzumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | FAP |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
216669-97-5  |
| ChemSpider | none |
 (what is this?) (verify) | |
Sibrotuzumab is a humanized monoclonal antibody intended for the treatment of cancer. It binds to FAP[1][2]
In 2003 it failed a phase II clinical trial for metastatic colorectal cancer.[3]
References
- ↑ Scott, AM; Wiseman, G; Welt, S; Adjei, A; Lee, FT; Hopkins, W; Divgi, CR; Hanson, LH; et al. (2003). "A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer". Clinical Cancer Research. 9 (5): 1639–47. PMID 12738716.
- ↑ Kloft, C; Graefe, EU; Tanswell, P; Scott, AM; Hofheinz, R; Amelsberg, A; Karlsson, MO (2004). "Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients". Investigational new drugs. 22 (1): 39–52. doi:10.1023/B:DRUG.0000006173.72210.1c. PMID 14707493.
- ↑ Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer.
This article is issued from Wikipedia - version of the 9/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.